細胞株開発の世界市場予測（2022年～2027年）

世界の細胞株開発の市場規模は、2020年に25億9,600万米ドルとなり、予測期間中に13.34％のCAGRで成長し、2027年に62億3,900万米ドルになると予測されています。

当レポートでは、世界の細胞株開発市場について調査し、市場規模や予測、COVID-19の影響、市場の促進要因および課題、市場動向、セグメント別の市場分析、競合情勢、主要企業のプロファイルなどの体系的な情報を提供しています。

目次

第1章 イントロダクション

• 市場概要
• COVID-19の影響
• 市場の定義
• 市場セグメンテーション

第2章 調査手法

• 調査データ
• 前提条件

第3章 エグゼクティブサマリー

• 調査のハイライト

第4章 市場力学

• 市場促進要因
• 市場抑制要因
• ポーターのファイブフォース分析
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• 業界のバリューチェーン分析

第5章 世界の細胞株開発市場：タイプ別

• イントロダクション
• 組換え細胞株
• ハイブリドーマ
• 連続細胞株
• 初代細胞株

第6章 世界の細胞株開発市場：原料別

• イントロダクション
• 哺乳類細胞株の開発
• 非哺乳類細胞株の開発

第7章 世界の細胞株開発市場：用途別

• 創薬
• 研究
• その他

第8章 世界の細胞株開発市場：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • スペイン
  • その他
• 中東・アフリカ
  • サウジアラビア
  • イスラエル
  • その他
• アジア太平洋地域
  • 中国
  • 日本
  • インド
  • 韓国
  • インドネシア
  • その他

第9章 競合環境と分析

• 主要企業と戦略分析
• 新興企業と市場の有利性
• 合併、買収、契約、コラボレーション
• ベンダーの競合マトリックス

第10章 企業プロファイル

• Lonza
• Biofactura
• WuXi AppTec
• KBI Biopharma
• ATUM
• Fusion Antibodies plc
• Selexis
• In Vivo
• Celonic AG
• Merck KGaA

The global cell line development market is projected to grow at a CAGR of 13.34% during the forecast period to reach US$6.239 billion by 2027, from US$2.596 billion in 2020.

A cell line is a permanently established cell culture that will proliferate indefinitely given appropriate fresh medium and space and is often used in place of primary cells to study biological processes. Cell line development refers to the process of developing stable cell lines for use in a number of important applications including biologics (e.g.recombinant protein and monoclonal antibody) production, drug screening, and gene functional studies. The process of cell line development includes transfection and selection and single-cell cloning. Further, the global cell line development market is segmented into type, source, and geography.

The growth of the global cell line development market is attributed to the rise in development and demand for monoclonal antibodies around the globe. The cell line development market will grow due to the rising demand for cell-based vaccines. The growing number of new virus outbreaks such as influenza, monkeypox, Ebola, and COVID-19 among others are contributing to the growing demand for cell-based vaccines. For instance, the World Health Organization's Disease Outbreak News (DONs), which provided confirmed acute public health events of potential events of concern reported the first case of the Ebola virus in April 2022. The Ministry of Health of the Democratic Republic of the Congo declared the outbreak of the Ebola virus following a confirmed laboratory test of a 31-year-old male in the North-western Equateur province. Furthermore, Uganda also witnessed a confirmed 18 cases as of 25th September 2022 Ebola virus which were caused by Sudan Virus. Such increasing cases of infectious diseases and the growing risk of pandemics are the prime factors driving the demand for vaccines worldwide.

Moreover, in June 2022, just after a few months of recovery from the disruptions of the COVID-19 pandemic, the outbreak of monkeypox in different countries alarmed the vaccine developer companies to take measures to control the spread of the new virus. Further, many organizations are putting efforts to develop vaccines for the rising disease. For instance, the Centers for Disease Control and Prevention (CDC) mentions in its Vaccine considerations summary updated in September 2022, that the JYNNEOS vaccine is approved for the prevention of monkeypox and smallpox diseases. Further, the ACAM2000 Vaccines has been approved for immunization against smallpox which is made available for use against monkeypox under Expanded Access Investigational New Drug protocol, mentions the CDC. As a result, the demand for vaccines is increasing globally, consequently increasing the demand for global cell line developments in the market and supporting the growth of the Global cell line development market during the anticipated period.

In the global cell line development market, it is expected that the North American region is expected to hold a significant share during the forecast period.

The rising research and development activities coupled with increasing investment in advanced processes and adoption of cell-based research in the countries like the US are driving the market in this region. Furthermore, the use of cell lines for biologics production, gene functional studies, and drug screening has further augmented the market's growth in the North American region. Moreover, the continuous work on vaccine development by the pharmaceutical companies operating in this region and their ambitious plans to expand their geographic reach is anticipated to fuel market expansion in this region.

Product offering

• KBI Biopharma offers mammalian cell line development can create mammalian protein expression systems by using cell line generation services like CHO-M Selexis SURE Technology. Furthermore, the company makes available both transient expression and stable pool generation approaches to aid proof-of-concept material generation for preclinical programs.
• Fusion Antibodies Plc. can deliver a range of mammalian cell lines to offer confidence and flexibility in supporting the users' clinical development. The company claims that it can cater to the requirement of rapid development of well-characterized mammalian cell lines with good clinical records.

COVID-19 Impact

The pandemic had a positive impact on the Global cell line development market. The virus spread rapidly across the globe through transmission and took approximately a million deaths till January 2021. Major pharmaceutical companies and start-ups stepped forward to develop vaccines to combat the rising risk of COVID-19. Many organizations and companies pushed their efforts of research and development to develop vaccines and drugs against the coronavirus. Furthermore, government and world organizations provided funding to increase the research on vaccines for the deadly coronavirus, which further increased the demand for cell culture products, including Global cell line development products during the pandemic.

Market Segments

• By Type

Recombinant Cell Lines

Hybridomas

Continuous Cell Lines

Primary Cell Lines

• By Source

Mammalian Cell Line Development

Non-Mammalian Cell Line Development

• By Application

Drug discovery

Research

Others

• By Geography

North America

• USA
• Canada
• Mexico

South America

• Brazil
• Argentina
• Others

Europe

• United Kingdom
• Germany
• France
• Spain
• Others

Middle East and Africa

• Saudi Arabia
• Israel
• Others

Asia Pacific

• China
• Japan
• India
• South Korea
• Indonesia
• Others

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Overview
• 1.2. COVID-19 Scenario
• 1.3. Market Definition
• 1.4. Market Segmentation

2. Research Methodology

• 2.1. Research Data
• 2.2. Assumptions

3. Executive Summary

• 3.1. Research Highlights

4. Market Dynamics

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Force Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. Global Cell Line Development Market, By Type

• 5.1. Introduction
• 5.2. Recombinant Cell Lines
• 5.3. Hybridomas
• 5.4. Continuous Cell Lines
• 5.5. Primary Cell Lines

6. Global Cell Line Development Market, By Source

• 6.1. Introduction
• 6.2. Mammalian Cell Line Development
• 6.3. Non-Mammalian Cell Line Development

7. Global Cell Line Development Market, By Application

• 7.1. Drug discovery
• 7.2. Research
• 7.3. Others

8. Global Cell Line Development Market, By Geography

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. The Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. Israel
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. Japan
  • 8.6.3. India
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Others

9. Competitive Environment and Analysis

• 9.1. Major Players and Strategy Analysis
• 9.2. Emerging Players and Market Lucrative
• 9.3. Mergers, Acquisition, Agreements, and Collaborations
• 9.4. Vendor Competitiveness Matrix

10. Company Profiles

• 10.1. Lonza
• 10.2. Biofactura
• 10.3. WuXi AppTec
• 10.4. KBI Biopharma
• 10.5. ATUM
• 10.6. Fusion Antibodies plc
• 10.7. Selexis
• 10.8. In Vivo
• 10.9. Celonic AG
• 10.10. Merck KGaA